MBX Biosciences, Inc. Common Stock
NASDAQ:MBX · NASDAQ Global Select
-$0.64 today
Vol 0.79M · Avg 0.65M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:MBX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$86.6M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.20, tying the income statement back to per-share earnings.
Income Statement
Annual data · 4 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.0B | $809.6M | $921.6M |
| Cost of Revenue | $248.0K | $0 | $0 | $0 | $344.8M | $725.6M | $804.0M |
| Gross Profit | -$248.0K | $0 | $0 | $0 | $10.3B | $8.9B | $7.6B |
| Gross Margin | — | — | — | — | 45.5% | 9.8% | 28.9% |
| Research & Development | $79.2M +37.9% | $57.4M +101.2% | $28.5M +33.4% | $21.4M | $378.4M | $983.2M | $1.3B |
| Selling, General & Admin | $18.9M +75.3% | $10.8M +59.1% | $6.8M +80.0% | $3.8M | $1.4B | $620.6M | $923.0M |
| Operating Expenses | $98.1M +43.8% | $68.2M +93.1% | $35.3M +40.3% | $25.2M | $3.6B | $5.3B | $7.0B |
| Depreciation & Amortization | $248.0K +1.6% | $244.0K +55.4% | $157.0K +180.4% | $56.0K | $1.2B | $374.2M | $1.2B |
| EBITDA | -$86.7M -40.6% | -$61.7M -90.3% | -$32.4M -26.1% | -$25.7M | $12.6B | -$15.2B | $6.8B |
| EBITDA Margin | — | — | — | — | 10.0% | 5.6% | 46.3% |
| Operating Income | -$98.1M -43.8% | -$68.2M -93.1% | -$35.3M -40.3% | -$25.2M | $10.6B | $12.3B | $14.0B |
| Operating Margin | — | — | — | — | 18.7% | 16.6% | 24.1% |
| Interest Income | $11.1M +76.7% | $6.3M +128.2% | $2.7M +638.7% | $372.0K | $1.3B | -$1.5B | -$1.6B |
| Interest Expense | $0 | $0 | $0 -100.0% | $374.0K | $969.2M | $1.1B | $1.0B |
| Other Income / Expenses | $11.1M +76.7% | $6.3M +128.2% | $2.7M +382.1% | -$974.0K | -$1.6B | -$1.5B | $1.4B |
| Income Before Tax | -$87.0M -40.5% | -$61.9M -90.2% | -$32.6M -24.6% | -$26.1M | -$15.6B | $3.3B | $4.9B |
| Pre-Tax Margin | — | — | — | — | 13.3% | 20.8% | 18.7% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $666.8M | $1.3B | -$1.6B |
| Net Income | -$87.0M -40.5% | -$61.9M -90.2% | -$32.6M -24.6% | -$26.1M | $5.0B | $4.9B | $4.8B |
| Net Margin | — | — | — | — | 7.4% | 12.4% | 17.5% |
| EPS (Basic) | -$2 -28.6% | -$2 -81.4% | -$1 -24.4% | -$1 | $1.2B | $400.8M | $703.2M |
| EPS (Diluted) | -$2 -28.6% | -$2 -81.4% | -$1 -24.4% | -$1 | $620.6M | $766.2M | $609.4M |
| Weighted Avg Shares | $36.5M +9.3% | $33.4M +4.8% | $31.9M +0.0% | $31.9M | $892.2M | $757.8M | $925.8M |
| Weighted Avg Shares (Diluted) | $36.5M +9.3% | $33.4M +4.8% | $31.9M +0.0% | $31.9M | $319.6M | $1.2B | $924.4M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Erasca, Inc.
NASDAQ:ERAS
$4.32B
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
$1.47B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.42B
Iovance Biotherapeutics, Inc.
NASDAQ:IOVA
$1.39B
MeiraGTx Holdings plc
NASDAQ:MGTX
$1.01B
Replimune Group, Inc.
NASDAQ:REPL
$831.51M
Astria Therapeutics, Inc.
ATXS
$718.13M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$581.39M
REGENXBIO Inc.
NASDAQ:RGNX
$410.48M
Verastem, Inc.
NASDAQ:VSTM
$291.81M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does MBX generate?
MBX Biosciences, Inc. Common Stock (MBX) reported $0.00 of revenue in fiscal 2025.
Is MBX profitable?
MBX Biosciences, Inc. Common Stock (MBX) reported -$86,971,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.